Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma

Dennis D. Weisenburger, Randy D. Gascoyne, Philip J. Bierman, Tamara Shenkier, Douglas E. Horsman, James C. Lynch, Wing C. Chan, Timothy C. Greiner, Joseph M. Connors, Julie M. Vose, James O. Armitage, Warren G. Sanger

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Follicular large cell lymphoma (FLCL) is an aggressive disease that responds to anthracycline-containing chemotherapy much like diffuse large B-cell lymphoma (DLBCL). Since the t(14;18) and/or bcl2 protein expression are less common in FLCL than in its low-grade counterparts, we sought to determine whether these features were predictive of survival as in DLBCL. We studied 50 patients with FLCL who were treated with curative intent. The t(14;18) was found by cytogenetic analysis in 56% of the patients and bcl2 protein was expressed by the tumor cells in 73%, but neither was predictive of survival. However, abnormalities of chromosome 17p and the presence of trisomy 21 were adverse predictors of survival, as were a number of clinical features. We conclude that neither the absence of the t(14;18) nor the lack of bcl2 expression explain the good response of a subset of patients with FLCL to curative therapy.

Original languageEnglish (US)
Pages (from-to)513-523
Number of pages11
JournalLeukemia and Lymphoma
Issue number5-6
StatePublished - 2000


  • BCL2
  • Cytogenetics
  • Follicular large cell lymphoma
  • Follicular lymphoma
  • Non-Hodgkin's lymphoma
  • T(14;18)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma'. Together they form a unique fingerprint.

Cite this